How Strong Oncology Sales and Raised Guidance Could Shape McKesson’s (MCK) Investment Narrative

Simply Wall St.

Nov 19

McKesson Corporation recently reported strong second-quarter results, with sales rising to US$103.15 billion and net income reaching US$1.11 billion, driven by increased prescription volumes and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2584991331"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584991331\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584991331?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044","is_english":true,"pubTime":"2025-11-19 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584991331","market":"sg","top_or_hot":-1,"title":"How Strong Oncology Sales and Raised Guidance Could Shape McKesson’s (MCK) Investment Narrative","media":"Simply Wall St.","content":"<div>\n<p>McKesson Corporation recently reported strong second-quarter results, with sales rising to US$103.15 billion and net income reaching US$1.11 billion, driven by increased prescription volumes and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-strong-oncology-sales-and-raised-guidance-could-shape-mc\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Strong Oncology Sales and Raised Guidance Could Shape McKesson’s (MCK) Investment Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Strong Oncology Sales and Raised Guidance Could Shape McKesson’s (MCK) Investment Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-19 11:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-strong-oncology-sales-and-raised-guidance-could-shape-mc><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>McKesson Corporation recently reported strong second-quarter results, with sales rising to US$103.15 billion and net income reaching US$1.11 billion, driven by increased prescription volumes and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-strong-oncology-sales-and-raised-guidance-could-shape-mc\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCK","symbol_name":"麦克森药物批发","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-strong-oncology-sales-and-raised-guidance-could-shape-mc","article_id":"2584991331","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-strong-oncology-sales-and-raised-guidance-could-shape-mc","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584991331","pubTimestamp":1763522537,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"McKesson Corporation recently reported strong second-quarter results, with sales rising to US$103.15 billion and net income reaching US$1.11 billion, driven by increased prescription volumes and expanded oncology and multispecialty distribution.\nThe company also raised its adjusted earnings guidance for Fiscal 2026, signaling confidence in ongoing momentum across its oncology, multispecialty, and biopharma services segments.\nWe'll assess how the raised earnings outlook, supported by record...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MCK":"麦克森药物批发"},"translate_title":"强劲的肿瘤销售和提高的指导如何塑造麦克森(MCK)的投资叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5},"content_text":"McKesson Corporation recently reported strong second-quarter results, with sales rising to US$103.15 billion and net income reaching US$1.11 billion, driven by increased prescription volumes and expanded oncology and multispecialty distribution. The company also raised its adjusted earnings guidance for Fiscal 2026, signaling confidence in ongoing momentum across its oncology, multispecialty, and biopharma services segments. We'll assess how the raised earnings outlook, supported by record sales in oncology and multispecialty, may influence McKesson's investment narrative. We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.AdvertisementMcKesson Investment Narrative RecapTo be a shareholder in McKesson today, you need to believe in the company's ability to consistently grow prescription and specialty pharmaceutical volumes amid a complex and evolving healthcare environment. The latest strong quarterly financials and raised earnings guidance may reinforce confidence in short-term momentum, but they do not fundamentally reduce the ongoing risk of regulatory pressure on drug pricing, the most significant headwind facing the business at present. Among recent updates, McKesson’s share buyback program stands out: the company repurchased 1.2 million shares for US$824.35 million last quarter, illustrating ongoing efforts to return capital to shareholders. While this supports near-term shareholder value, the buyback activity does not materially shift the risk profile tied to healthcare policy and market structure changes, which remain crucial to the broader investment thesis. Yet, in contrast to McKesson’s strong quarter, investors should be aware of the potential for increased government pricing pressure... Read the full narrative on McKesson (it's free!)McKesson's outlook forecasts $478.8 billion in revenue and $5.3 billion in earnings by 2028. This scenario requires 8.2% annual revenue growth and a $2.1 billion increase in earnings from the current $3.2 billion.Uncover how McKesson's forecasts yield a $844.57 fair value, in line with its current price.Exploring Other PerspectivesMCK Community Fair Values as at Nov 2025 Four fair value estimates from the Simply Wall St Community range from US$665 to US$1,399, capturing wide differences in outlook. As prescription volume growth powers optimism, consider how regulatory headwinds could influence those projections before forming your own view.Explore 4 other fair value estimates on McKesson - why the stock might be worth 23% less than the current price!Build Your Own McKesson NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your McKesson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Neodymium and there are only 37 companies in the world exploring or producing it. Find the list for free.These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}